Clinical Trials Logo

Hereditary Cancer Syndrome clinical trials

View clinical trials related to Hereditary Cancer Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03857594 Active, not recruiting - Mutation Clinical Trials

Integrative Sequencing In Germline and Hereditary Tumours

INSIGHT
Start date: October 2, 2018
Phase:
Study type: Observational

This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative sequencing refers to: 1. Whole genome sequencing (WGS) of the germline (inherited) genome 2. Whole exome sequencing (WES) or targeted/panel sequencing of tumour(s) (somatic, tumour-specific mutations) 3. DNA methylation (methylome) analysis of tumour(s) 4. RNA sequencing (transcriptome) of tumour(s) Eligible patients receiving genetic care at Princess Margaret Cancer Centre and the University Health Network may be approached by their genetic counsellor for participation in this study.

NCT ID: NCT03426878 Active, not recruiting - Clinical trials for Hereditary Cancer Syndrome

Cancer Health Assessments Reaching Many

CHARM
Start date: August 15, 2018
Phase: N/A
Study type: Interventional

The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators will assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators will also assess the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.